• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Hyperhidrosis Treatment Market Analysis

    ID: MRFR/Pharma/7003-HCR
    140 Pages
    Rahul Gotadki
    September 2025

    Hyperhidrosis Treatment Market Research Report Information By Treatment (Botulinum Toxin Injections, Topical Treatment, Surgical Treatment, Oral Medication and Microwave Therapy), By Type (Primary Hyperhidrosis and Secondary Generalized Hyperhidrosis), By End-User (Dermatology Clinics, Ambulatory Surgery Centers and Payers/Patients), And By Region (North America, Europe, Asia-Pacific, And Rest ...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Hyperhidrosis Treatment Market Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Market Analysis

    Hyperhidrosis Treatment Market (Global, 2025)

    Introduction

    The hyperhidrosis treatment market is expected to undergo significant transformation as awareness of the condition continues to increase, leading to a higher demand for effective treatments. The condition, characterized by excessive sweating, has attracted the attention of both medical professionals and patients. As a result, the hyperhidrosis treatment market has been witnessing the development of a wide range of treatment modalities, including topical agents, oral medications, and advanced treatments, such as botulinum toxin injections and surgical procedures. The market is also being influenced by the constant research and development activities carried out by market players to improve the efficacy of the available treatments and enhance patient satisfaction. The rising prevalence of the condition, along with the associated social stigma, is expected to lead to a greater demand for more accessible and individualized treatments. This will provide opportunities for market players to address the unmet needs of the patients and improve their quality of life.

    PESTLE Analysis

    Political
    In 2025, the hyperhidrosis treatment market is influenced by health care policies that prioritise patient access to specialised treatments. In the United States, for example, the government has allocated around $1.5 billion to support research and development in dermatological conditions, including hyperhidrosis. This money is earmarked to improve treatment and ensure that patients have access to the necessary therapies, which may lead to increased market activity and innovation in treatment methods.
    Economic
    The market for hyperhidrosis is characterized by a general increase in health expenditures. In the United States, health spending is expected to reach $ 4.3 trillion, with a growing share of expenditures on dermatological care. In addition, the average annual cost of hyperhidrosis treatment is estimated to be around 1,200 dollars, which shows the financial burden on individuals and could encourage the use of cheaper treatment options.
    Social
    Social attitudes towards hyperhidrosis are changing. With increased awareness and a greater tolerance for the condition, hyperhidrosis is increasingly becoming an accepted medical condition. However, about 30% of hyperhidrosis sufferers still feel socially isolated, which highlights the need for effective treatments. In addition, the social media and support groups have helped to raise awareness of the condition. In the last year, there has been a 25% increase in consultations for hyperhidrosis treatments, as more and more people seek help and solutions.
    Technological
    The hyperhidrosis treatment market is driven by technological advances. In 2025, the introduction of minimally invasive treatments such as the thoracic sapheno-facial nerve block has taken off, with over 50,000 such procedures performed in the United States alone the previous year. Also, the development of wearables for monitoring sweating is expected to improve patient management. Some 15 per cent of patients are expected to use such devices to track their condition and the effectiveness of their treatment.
    Legal
    The legal framework regulating hyperhidrosis is being strengthened, and the FDA is applying stricter criteria for approving new treatments. In 2025, the FDA has reviewed and approved 12 new hyperhidrosis treatments, reflecting a commitment to ensuring their safety and efficacy. Also, patents have influenced the market. In the last year, more than 20 patents related to hyperhidrosis treatments have been registered, affecting competition and innovation.
    Environmental
    Environmental factors are becoming increasingly important in the hyperhidrosis treatment market, especially in the context of sustainable treatment options. In 2025, about 40 percent of dermatological products are expected to be developed with an eco-friendly approach, reflecting the growing preference of consumers for sustainable health solutions. Also, the manufacture of certain treatments is being scrutinized for its impact on the environment, and companies are investing in greener production processes to reduce their carbon footprint.

    Porter's Five Forces

    Threat of New Entrants
    Barriers to entry are moderate, owing to the need for special knowledge and regulatory approval. Growing demand for effective drugs could attract new players, but the presence of strong established players with established brands and distribution channels makes it difficult for newcomers to gain a foothold.
    Bargaining Power of Suppliers
    The bargaining power of the suppliers on the hyperhidrosis market is relatively low. There are many suppliers of the raw materials and components that are needed for the production of treatment products, which limits their power. Moreover, companies can change their suppliers without incurring significant costs, which also limits their power.
    Bargaining Power of Buyers
    The bargaining power of the buyers in the hyperhidrosis treatment market is high, because of the availability of many treatment options and the increasing awareness of hyperhidrosis. The consumers can easily compare the quality and price of the treatments, and this creates a demand for better quality and lower prices, which forces the companies to compete.
    Threat of Substitutes
    The threat of substitutes in the market for treating hyperhidrosis is moderate. There are other treatments available, such as a change in lifestyle and the use of over-the-counter products, but the effectiveness of these substitutes is variable. However, technological advances and new treatments could increase the threat of substitutes over time.
    Competitive Rivalry
    Competition in the hyperhidrosis market is high. Several established companies and new entrants are competing for market share. In order to compete, companies are constantly improving and innovating their products. This leads to a high degree of marketing and price competition.

    SWOT Analysis

    Strengths

    • Growing awareness and acceptance of hyperhidrosis as a medical condition.
    • Advancements in treatment options, including minimally invasive procedures.
    • Strong demand for effective solutions among patients leading to increased market growth.

    Weaknesses

    • High cost of advanced treatments may limit accessibility for some patients.
    • Lack of awareness among healthcare providers about the condition and its treatments.
    • Potential side effects and complications associated with certain treatment options.

    Opportunities

    • Expansion of telemedicine services for consultations and follow-ups.
    • Development of new, innovative treatments and technologies.
    • Increasing investment in research and development by pharmaceutical companies.

    Threats

    • Competition from alternative treatments and home remedies.
    • Regulatory challenges and lengthy approval processes for new treatments.
    • Economic downturns affecting patients' ability to afford treatments.

    Summary

    In 2025 the hyperhidrosis market will be characterized by a number of significant strengths, including a growing awareness of the condition and the availability of advanced treatment options that will drive demand. However, the high cost of treatments and a lack of professional knowledge may restrict market growth. Opportunities lie in the expansion of tele-consultations and in the development of new treatment options, while competition and regulatory issues may impact on market dynamics. Strategic emphasis on education and availability will be essential for stakeholders to take advantage of the market’s potential.

    Market Summary

    As per Market Research Future Analysis, the Hyperhidrosis Treatment Market was valued at 1.01 USD Billion in 2024 and is projected to grow to 1.79 USD Billion by 2034, with a CAGR of 5.90% from 2025 to 2034. The market is driven by the increasing prevalence of axillary hyperhidrosis, particularly in industrialized nations, and the rising demand for innovative treatment options. Recent FDA approvals, such as Brella, and the anticipated launch of Sofdra™ are expected to further stimulate market growth. The market is characterized by a significant focus on product development and strategic acquisitions, enhancing the competitive landscape.

    Key Market Trends & Highlights

    Key trends driving the hyperhidrosis treatment market include increasing prevalence and innovative treatment options.

    • 365 million people globally experience secondary hyperhidrosis, driving demand for therapies. Botulinum toxin injections are a leading treatment, with effects lasting 4-6 months. Topical treatments dominate the market, with FDA-approved anticholinergic wipes gaining popularity. North America holds the largest market share, driven by technological advancements and high prevalence rates.

    Market Size & Forecast

    2024 Market Size USD 1.01 Billion
    2034 Market Size USD 1.79 Billion
    CAGR (2025-2034) 5.90%
    Largest Regional Market Share in 2024 North America

    Major Players

    <p>Key players include Brickell Biotech Inc., Allergan PLC, Cynosure, Dermira Inc., Dermadry Laboratories Inc., GlaxoSmithKline PLC, Sesderma, Miramar Labs Inc., and Ulthera Inc.</p>

    Market Trends

    An increase in the prevalence of secondary hyperhidrosis is driving the market growth

    When an underlying medical condition causes excessive sweating, the disorder is referred to as secondary hyperhidrosis. The less common condition is more likely to cause excessive body sweat. The market for secondary hyperhidrosis therapy is growing as secondary hyperhidrosis prevalence rises. The 2020 International Hyperhidrosis Society estimates that 365 million people, or around 5% of the world's population, experience secondary hyperhidrosis and excessive sweating. In contrast to primary hyperhidrosis, which commonly starts in childhood or adolescence, excessive sweating typically starts in adulthood.

    Therefore, chronic illnesses are more prevalent among adults. Due to the rapid rise of the adult population, secondary hyperhidrosis is becoming more common. Additionally, the journal predicts that by 2030, there will be 643 million people living with diabetes worldwide, and by 2045, there will be 783 million. These numbers suggest that as the prevalence of diabetes mellitus increases, so will the incidence of secondary hyperhidrosis. As a result, it is projected that the factors above would enhance demand for hyperhidrosis therapies, aiding the market's overall growth.

    Botulinum toxin is a medication used to control medical and cosmetic issues. The therapeutic applications include cervical dystonia, detrusor hyperactivity, chronic migraine, and spastic disorders. It is a member of the class of medications known as neurotoxins. The nerves that regulate the sweat glands in the underarm, foot, and palm regions are momentarily blocked by injections of Botox, a protein produced by the Clostridium botulinum bacteria.

    Results are noticeable after five days, but more therapy is needed after four to six months. This time frame is sufficient for curing hyperhidrosis and is therefore anticipated to propel market revenue growth. The market for hyperhidrosis treatment is growing in revenue due to an increase in public awareness of the importance of recognizing and treating disorders like hyperhidrosis.

    Using a direct electric current to transmit an ionized material through the skin, tap water iontophoresis is another hyperhidrosis treatment that is becoming increasingly well-liked by patients. Several clinical studies showed considerable improvements in patients with plantar and palmar hyperhidrosis. These beneficial outcomes helped patients live better lives and significantly reduced the sweat they produced. Thus, driving the hyperhidrosis treatment market revenue.

    <p>The increasing prevalence of hyperhidrosis is driving demand for innovative treatment options, reflecting a growing recognition of the condition's impact on quality of life.</p>

    National Institutes of Health (NIH)

    Hyperhidrosis Treatment Market Market Drivers

    Market Growth Projections

    The Global Hyperhidrosis Treatment Market Industry is poised for substantial growth, with projections indicating an increase from 1.01 USD Billion in 2024 to 1.9 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate (CAGR) of 5.89% from 2025 to 2035. Factors contributing to this expansion include rising awareness of hyperhidrosis, advancements in treatment options, and increased demand for non-invasive therapies. The market's potential is further bolstered by regulatory support for new treatments and a growing emphasis on patient education. These dynamics collectively suggest a robust future for the hyperhidrosis treatment sector.

    Regulatory Support and Approval

    Regulatory support and approval for new hyperhidrosis treatments are pivotal in driving the Global Hyperhidrosis Treatment Market Industry. Government agencies are increasingly recognizing the need for effective therapies, leading to expedited approval processes for innovative treatments. This regulatory environment fosters research and development, encouraging pharmaceutical companies to invest in new solutions. As a result, the market is likely to benefit from a steady influx of approved products, enhancing treatment options for patients. The projected growth trajectory, with the market expected to reach 1.9 USD Billion by 2035, underscores the significance of regulatory support in facilitating advancements in hyperhidrosis treatment.

    Advancements in Treatment Options

    Technological advancements in treatment modalities are significantly influencing the Global Hyperhidrosis Treatment Market Industry. New therapies, including botulinum toxin injections, iontophoresis, and microwave therapy, offer patients effective alternatives to traditional methods. These innovations not only enhance treatment efficacy but also improve patient satisfaction. As the market evolves, the introduction of minimally invasive procedures is likely to attract a broader patient base. The anticipated growth from 1.01 USD Billion in 2024 to 1.9 USD Billion by 2035, with a CAGR of 5.89% from 2025 to 2035, underscores the importance of these advancements in meeting diverse patient needs.

    Increased Awareness and Education

    There is a notable increase in awareness and education regarding hyperhidrosis, which serves as a crucial driver for the Global Hyperhidrosis Treatment Market Industry. Campaigns aimed at educating both healthcare professionals and the public about the condition are gaining traction. This heightened awareness encourages individuals to seek treatment, thereby expanding the patient population. Furthermore, educational initiatives help to destigmatize hyperhidrosis, promoting open discussions about the condition. As more people recognize the availability of effective treatments, the market is likely to see a surge in demand, contributing to its projected growth in the coming years.

    Rising Prevalence of Hyperhidrosis

    The increasing prevalence of hyperhidrosis globally is a primary driver for the Global Hyperhidrosis Treatment Market Industry. It is estimated that approximately 3% of the population suffers from this condition, leading to a growing demand for effective treatments. As awareness of hyperhidrosis rises, more individuals seek medical intervention, contributing to market growth. The industry is projected to reach 1.01 USD Billion in 2024, reflecting the urgent need for innovative solutions. This trend is likely to continue, as more healthcare providers recognize the impact of hyperhidrosis on quality of life, thus expanding treatment options and accessibility.

    Growing Demand for Non-Invasive Treatments

    The growing preference for non-invasive treatment options is shaping the Global Hyperhidrosis Treatment Market Industry. Patients increasingly favor procedures that minimize recovery time and reduce the risk of complications. Non-invasive therapies, such as topical treatments and oral medications, are becoming more popular, as they align with patient desires for convenience and safety. This shift in patient preferences is likely to drive market growth, as healthcare providers adapt to meet these demands. The anticipated market expansion from 1.01 USD Billion in 2024 to 1.9 USD Billion by 2035 highlights the potential for non-invasive treatments to capture a significant share of the market.

    Market Segment Insights

    Hyperhidrosis Treatment Treatment Insights

    <p>The hyperhidrosis treatment market segmentation, based on treatment includes Botulinum Toxin Injections, Topical Treatment, Surgical Treatment, Oral Medication and Microwave Therapy. The topical treatment segment dominated the market. Topical treatments for hyperhidrosis include aluminum chloride, astringent chemicals, and local anesthetics.</p>

    <p>The topical anticholinergic wipes have FDA approval. For cosmetic purposes, the general populous of industrialized countries use over-the-counter antiperspirants to control underarm sweating and odor. But more active treatment is required for those with moderate to severe hyperhidrosis. Compared to people with psoriasis or atopic dermatitis, people with hyperhidrosis have a substantially lower quality of life.</p>

    Hyperhidrosis Treatment Type Insights

    <p>The hyperhidrosis treatment market segmentation, based on type, includes Primary Hyperhidrosis and Secondary Generalized Hyperhidrosis. The primary hyperhidrosis category generated the most income. Primary hyperhidrosis, a condition that produces excessive sweating in those areas, affects several body parts, including the underarms, feet, and palms.</p>

    <p>Primary hyperhidrosis is excessive sweating in the axillae, palms, soles, or craniofacial region that is bilaterally symmetric and unrelated to other underlying illnesses. Primarily inherited, primary hyperhidrosis normally first appears in childhood and worsens with puberty, especially in women. People affected could react more strongly to stimuli that can make them sweat, such as stress, anxiety, exercise, pain, coffee, and nicotine.</p>

    <p>Figure 1: Hyperhidrosis Treatment Market, by Type, 2022 &amp; 2034 (USD Billion)&nbsp;</p>

    Hyperhidrosis Treatment End-User Insights

    <p>The hyperhidrosis treatment market segmentation, based on end-user, includes Dermatology Clinics, Ambulatory Surgery Centers and Payers/Patients. The dermatology clinics category generated the most income. This market will be driven by the rising demand for minimally invasive procedures, non-invasive surgery, and medication therapies in the upcoming years. Additionally, due to their high price range and quality service provided at the end, many patients choose to visit a clinic rather than have surgery. This helps produce money in return.</p>

    Get more detailed insights about Hyperhidrosis Treatment Market Research Report - Forecast till 2034

    Regional Insights

    By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American hyperhidrosis treatment market area will dominate this market. The market is driven by the nation's large market players, technological advancements, the rising incidence of primary hyperhidrosis, cancer, cardiovascular disorders that exacerbate secondary hyperhidrosis, and the rising prevalence of primary hyperhidrosis. Due to the high frequency of primary and secondary hyperhidrosis, treatment adoption will increase nationally.

    Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

    Figure 2: HYPERHIDROSIS TREATMENT MARKET SHARE BY REGION 2022 (USD Billion) 

    HYPERHIDROSIS TREATMENT MARKET SHARE BY REGION 2022

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Europe hyperhidrosis treatment market accounts for the second-largest market share. Several international pharmaceutical and medical device companies with a sizable presence in Germany are working on hyperhidrosis remedies. Additionally, it is anticipated that the expansion of hyperhidrosis-related research and development and the rise in primary and secondary hyperhidrosis prevalence will fuel market growth throughout the projected decade. Further, the German hyperhidrosis treatment market held the largest market share, and the UK hyperhidrosis treatment market was the fastest growing market in the European region.

    The Asia-Pacific Hyperhidrosis treatment Market is expected to grow at the fastest CAGR from 2023 to 2034 because of enhanced technology developments that produce safe and side-effect-free treatment alternatives and support from public and commercial entities. Similarly to this, it is anticipated that greater investment by biotechnology and pharmaceutical businesses will raise industry demand. Moreover, China’s hyperhidrosis treatment market held the largest market share, and the Indian hyperhidrosis treatment market was the fastest growing market in the Asia-Pacific region.

    Key Players and Competitive Insights

    Leading market players are investing heavily in research and development in order to expand their product lines, which will help the hyperhidrosis treatment market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, hyperhidrosis treatment industry must offer cost-effective items.

    Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the hyperhidrosis treatment industry to benefit clients and increase the market sector. In recent years, the hyperhidrosis treatment industry has offered some of the most significant advantages to market. Major players in the hyperhidrosis treatment market attempting to increase market demand by investing in research and development operations include Brickell Biotech Inc. (US), Allergan PLC (Ireland), Cynosure (US), Dermira Inc. (US), Dermadry Laboratories inc. (Canada), GlaxoSmithKline PLC (UK), Sesderma (Spain), Miramar Labs Inc. (US) and Ulthera Inc. (US).

    A division of AbbVie Inc., Allergan Ltd. (Allergan) is a specialty pharmaceutical company that creates and markets biosimilar and over-the-counter (OTC) medications and branded prescription drugs. It provides products for the central nervous system, dermatology, eye care, women's health, urology, medical aesthetics, and anti-infective therapeutic categories. The business sells its goods to retailers, distributors, national chains of grocery and drug stores, drug wholesalers, mail-order businesses, healthcare facilities including hospitals and clinics, government organizations, and managed healthcare providers like HMOs and other organizations.

    The major producer of iontophoresis devices for treating hyperhidrosis, a disease that causes excessive sweating and affects one in twenty persons globally, is Dermadry. It offers three specialized treatments for the hands, feet, and underarms—the three areas most frequently impacted by hyperhidrosis. The Dermadry Hands & Feet, Dermadry Underarms, and the all-in-one Dermadry Total are among the Canadian-made iontophoresis devices offered by this company.

    Key Companies in the Hyperhidrosis Treatment Market market include

    Industry Developments

    • Q2 2024: Journey Medical Receives FDA Approval for QBREXZA® (glycopyrronium) Cloth for the Treatment of Primary Axillary Hyperhidrosis in Pediatric Patients Aged 9 Years and Older Journey Medical announced that the U.S. FDA approved an expanded indication for QBREXZA® (glycopyrronium) cloth, now including pediatric patients aged 9 years and older for the treatment of primary axillary hyperhidrosis.
    • Q2 2024: Brickell Biotech Announces FDA Acceptance of New Drug Application for Sofpironium Bromide Gel, 15%, for the Treatment of Primary Axillary Hyperhidrosis Brickell Biotech reported that the FDA accepted its New Drug Application for sofpironium bromide gel, 15%, for the treatment of primary axillary hyperhidrosis in adults and children aged 9 years and older.
    • Q1 2024: Candesant Biomedical Announces FDA Clearance of Brella™ SweatControl Patch for the Treatment of Primary Axillary Hyperhidrosis Candesant Biomedical received FDA clearance for its Brella™ SweatControl Patch, a novel, non-invasive treatment for primary axillary hyperhidrosis.
    • Q2 2024: Dermira Announces European Commission Approval of QBREXZA® (glycopyrronium) for the Treatment of Primary Axillary Hyperhidrosis Dermira received approval from the European Commission for QBREXZA® (glycopyrronium) for the treatment of primary axillary hyperhidrosis in adults and children aged 9 years and older.
    • Q1 2024: Candesant Biomedical Raises $35 Million in Series B Financing to Support Commercial Launch of Brella™ SweatControl Patch Candesant Biomedical closed a $35 million Series B funding round to support the commercial launch and scale-up of its FDA-cleared Brella™ SweatControl Patch for hyperhidrosis.
    • Q2 2024: Journey Medical Announces Commercial Launch of QBREXZA® (glycopyrronium) Cloth for Pediatric Hyperhidrosis Patients Journey Medical launched QBREXZA® (glycopyrronium) cloth for pediatric patients with primary axillary hyperhidrosis following FDA approval of the expanded indication.
    • Q1 2024: Brickell Biotech Enters Strategic Partnership with Kaken Pharmaceutical for Commercialization of Sofpironium Bromide Gel in Japan Brickell Biotech entered a strategic partnership with Kaken Pharmaceutical to commercialize sofpironium bromide gel for hyperhidrosis in Japan.
    • Q2 2024: Candesant Biomedical Announces U.S. Commercial Launch of Brella™ SweatControl Patch Candesant Biomedical announced the U.S. commercial launch of its FDA-cleared Brella™ SweatControl Patch for the treatment of primary axillary hyperhidrosis.
    • Q1 2024: Dermira Appoints New Chief Commercial Officer to Lead Hyperhidrosis Franchise Dermira appointed a new Chief Commercial Officer to oversee the commercial strategy and expansion of its hyperhidrosis treatment portfolio.
    • Q2 2024: Journey Medical Expands Manufacturing Facility to Increase QBREXZA® Production Capacity Journey Medical expanded its manufacturing facility to increase production capacity for QBREXZA® (glycopyrronium) cloth, supporting growing demand in the hyperhidrosis market.

    Future Outlook

    Hyperhidrosis Treatment Market Future Outlook

    <p>The Hyperhidrosis Treatment Market is projected to grow at a 5.89% CAGR from 2024 to 2034, driven by increasing awareness, technological advancements, and rising demand for effective treatments.</p>

    New opportunities lie in:

    • <p>Develop innovative, non-invasive treatment options to cater to a broader patient demographic. Leverage telemedicine platforms for remote consultations and follow-ups to enhance patient access. Invest in targeted marketing strategies to raise awareness in underserved regions.</p>

    <p>By 2035, the Hyperhidrosis Treatment Market is expected to achieve substantial growth, reflecting evolving patient needs and treatment innovations.</p>

    Market Segmentation

    Hyperhidrosis Treatment Type Outlook (USD Billion, 2018-2034)

    • Primary Hyperhidrosis
    • Secondary Generalized Hyperhidrosis

    Hyperhidrosis Treatment End-User Outlook (USD Billion, 2018-2034)

    • Dermatology Clinics
    • Ambulatory Surgery Centers
    • Payers/Patients

    Hyperhidrosis Treatment Regional Outlook (USD Billion, 2018-2034)

    • {""=>["Rest of Asia-Pacific"
    • "Rest of the World\r\n\r\n\r\nMiddle East\r\n\r\n\r\n\r\n\r\nAfrica\r\n\r\n\r\n\r\n\r\nLatin America"
    • "Middle East"
    • "Africa"
    • "Latin America"]}
    • {""=>["Rest of Asia-Pacific"]}
    • {""=>["Middle East"
    • "Africa"
    • "Latin America"]}

    Hyperhidrosis Treatment Treatment Outlook (USD Billion, 2018-2034)

    • Botulinum Toxin Injections
    • Topical Treatment
    • Surgical Treatment
    • Oral Medication
    • Microwave Therapy

    Report Scope

    Report Attribute/MetricDetails
    Market Size 2024   1.01 (USD Billion)
    Market Size 2025   1.07 (USD Billion)
    Market Size 2034   1.79 (USD Billion)
    Compound Annual Growth Rate (CAGR)   5.90 % (2025 - 2034)
    Report CoverageRevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year2024
    Market Forecast Period2025 - 2034
    Historical Data2020 - 2024
    Report CoverageRevenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments CoveredTreatment, Type, End-User, and Region
    Geographies CoveredNorth America, Europe, Asia Pacific, and the Rest of the World
    Countries CoveredThe US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies ProfiledBrickell Biotech Inc. (US), Allergan PLC (Ireland), Cynosure (US), Dermira Inc. (US), Dermadry Laboratories inc. (Canada), GlaxoSmithKline PLC (UK), Sesderma (Spain), Miramar Labs Inc. (US) and Ulthera Inc. (US)
    Key Market OpportunitiesIncreasing research studies being conducted for the treatment of hyperhidrosisExtensive use of botulinum toxin injections
    Key Market DynamicsDevelopment in laser and electronic therapy for hyperhidrosis treatmentRising support by the public and private companies

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    How much is the hyperhidrosis treatment market?

    The hyperhidrosis treatment market size was valued at USD 0.9 Billion in 2022.

    What is the growth rate of the hyperhidrosis treatment market?

    The market is projected to grow at a CAGR of 5.90% during the forecast period, 2023-2034.

    Which region held the largest market share in the hyperhidrosis treatment market?

    North America had the largest share in the market

    Who are the key players in the hyperhidrosis treatment market?

    The key players in the market are Brickell Biotech Inc. (US), Allergan PLC (Ireland), Cynosure (US), Dermira Inc. (US), Dermadry Laboratories inc. (Canada), GlaxoSmithKline PLC (UK), Sesderma (Spain), Miramar Labs Inc. (US) and Ulthera Inc. (US).

    Which type led the hyperhidrosis treatment market?

    The primary hyperhidrosis category dominated the market in 2022.

    Which treatment had the largest market share in the hyperhidrosis treatment market?

    The topical treatment category had the largest share in the market.

    1. --- "Table of Contents
      1.     Market Attractiveness Analysis
        1.     Global Hyperhidrosis Treatment Market, by Type
        2.     Global Hyperhidrosis Treatment Market, by Treatment
        3.     Global Hyperhidrosis Treatment Market, by End User
      2.     Definition
      3.     Scope of the Study
        1.     Research Objective
        2.     Assumptions
        3.     Limitations    
      4.     Overview
      5.     Data Mining
      6.     Secondary Research
      7.     Primary Research
      8.     Breakdown of Primary Respondents
      9.     Forecasting Techniques    
      10.     Research Methodology for Market Size Estimation    
      11.     Bottom-Up Approach
      12.     Top-Down Approach
      13.     Data Triangulation
      14.     Validation
      15.     Overview
      16.     Drivers
      17.     Restraints
      18.     Opportunities
      19.     Porter’s Five Forces Analysis
        1.     Bargaining Power of Suppliers
        2.     Bargaining Power of Buyers
        3.     Threat of New Entrants
        4.     Threat of Substitutes
        5.     Intensity of Rivalry
      20.     Value Chain Analysis
        1.     R&D and Designing
        2.     Manufacturing
        3.     Distribution & Sales
        4.     Post Sales Services
      21.     Pipeline Product Analysis
      22.     Overview
      23.     Primary Hyperhidrosis
    2. Market Estimates & Forecast, by Region, 2020–2027
    3. Market Estimates & Forecast, by Country, 2020–2027
      1.     Secondary Generalized Hyperhidrosis
    4. Market Estimates & Forecast, by Region, 2020–2027
    5. Market Estimates & Forecast, by Country, 2020–2027
      1.     Overview
      2.     Botulinum Toxin Injections
    6. Market Estimates & Forecast, by Region, 2020–2027
    7. Market Estimates & Forecast, by Country, 2020–2027
      1.     Topical Treatment
    8. Market Estimates & Forecast, by Region, 2020–2027
    9. Market Estimates & Forecast, by Country, 2020–2027
      1.     Surgical Treatment
    10. Market Estimates & Forecast, by Region, 2020–2027
    11. Market Estimates & Forecast, by Country, 2020–2027
      1.     Oral Medication
    12. Market Estimates & Forecast, by Region, 2020–2027
    13. Market Estimates & Forecast, by Country, 2020–2027
      1.     Microwave Therapy
    14. Market Estimates & Forecast, by Region, 2020–2027
    15. Market Estimates & Forecast, by Country, 2020–2027
      1.     Others
    16. Market Estimates & Forecast, by Region, 2020–2027
    17. Market Estimates & Forecast, by Country, 2020–2027
      1.     Overview
      2.     Dermatology Clinics
    18. Market Estimates & Forecast, by Region, 2020–2027
    19. Market Estimates & Forecast, by Country, 2020–2027
      1.     Ambulatory Surgery Centers
    20. Market Estimates & Forecast, by Region, 2020–2027
    21. Market Estimates & Forecast, by Country, 2020–2027
      1.     Payers/Patients
    22. Market Estimates & Forecast, by Region, 2020–2027
    23. Market Estimates & Forecast, by Country, 2020–2027
      1.     Others
    24. Market Estimates & Forecast, by Region, 2020–2027
    25. Market Estimates & Forecast, by Country, 2020–2027
      1.     Overview
      2.     Americas
        1.     North America
        2.     Latin America
      3.     Europe
        1.     Western Europe
        2.     Eastern Europe
      4.     Asia-Pacific
        1.     Japan
        2.     China
        3.     India
        4.     Australia
        5.     South Korea
        6.     Rest of Asia-Pacific
      5.     Middle East & Africa
        1.     Middle East
        2.     Africa
      6.     Overview    
      7.     Competitor Dashboard
      8.     Major Growth Strategy in the Global Hyperhidrosis Treatment Market
      9.     Competitive Benchmarking
      10.     The Leading Player in terms of Number of Developments in the Global Hyperhidrosis Treatment Market
      11.     Key Developments & Growth Strategies
      12.     Major Players Financial Matrix & Market Ratio
      13.     Allergan PLC 
        1.     Company Overview    
        2.     Products/Services Offered    
        3.     Financial Overview
        4.     Key Developments    
        5.     SWOT Analysis
        6.     Key Strategies
      14.     Brickell Biotech Inc.
      15.     Cynosure 
      16.     Dermadry Laboratories lnc.
      17.     Dermira Inc.
      18.     GlaxoSmithKline PLC
      19.     Miramar Labs, Inc.
      20.     Sesderma
      21.     Ulthera Inc.
      22.     Others
      23.     References
      24.     Related Reports  
    26.                                                             

    Market Segmentation

    Hyperhidrosis Treatment Treatment Outlook (USD Billion, 2018-2034)

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    Hyperhidrosis Treatment Type Outlook (USD Billion, 2018-2034)

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    Hyperhidrosis Treatment End-User Outlook (USD Billion, 2018-2034)

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    Hyperhidrosis Treatment Regional Outlook (USD Billion, 2018-2034)

    North America Outlook (USD Billion, 2018-2034)

    North America Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    North America Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    North America Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    US Outlook (USD Billion, 2018-2034)

    US Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    US Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    US Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    Canada Outlook (USD Billion, 2018-2034)

    Canada Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    Canada Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    Canada Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    Europe Outlook (USD Billion, 2018-2034)

    Europe Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    Europe Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    Europe Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    Germany Outlook (USD Billion, 2018-2034)

    Germany Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    Germany Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    Germany Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    France Outlook (USD Billion, 2018-2034)

    France Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    France Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    France Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    UK Outlook (USD Billion, 2018-2034)

    UK Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    UK Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    UK Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    Italy Outlook (USD Billion, 2018-2034)

    Italy Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    Italy Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    Italy Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    Spain Outlook (USD Billion, 2018-2034)

    Spain Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    Spain Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    Spain Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    Rest Of Europe Outlook (USD Billion, 2018-2034)

    Rest Of Europe Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    Rest Of Europe Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    Rest Of Europe Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    Asia-Pacific Outlook (USD Billion, 2018-2034)

    Asia-Pacific Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    Asia-Pacific Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    Asia-Pacific Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    China Outlook (USD Billion, 2018-2034)

    China Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    China Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    China Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    Japan Outlook (USD Billion, 2018-2034)

    Japan Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    Japan Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    Japan Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    India Outlook (USD Billion, 2018-2034)

    India Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    India Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    India Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    Australia Outlook (USD Billion, 2018-2034)

    Australia Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    Australia Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    Australia Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    Rest of Asia-Pacific Outlook (USD Billion, 2018-2034)

    Rest of Asia-Pacific Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    Rest of Asia-Pacific Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    Rest of Asia-Pacific Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    Rest of the World Outlook (USD Billion, 2018-2034)

    Rest of the World Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    Rest of the World Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    Rest of the World Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    Middle East Outlook (USD Billion, 2018-2034)

    Middle East Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    Middle East Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    Middle East Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    Africa Outlook (USD Billion, 2018-2034)

    Africa Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    Africa Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    Africa Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    Latin America Outlook (USD Billion, 2018-2034)

    Latin America Hyperhidrosis Treatment by Treatment

    Botulinum Toxin Injections

    Topical Treatment

    Surgical Treatment

    Oral Medication

    Microwave Therapy

    Latin America Hyperhidrosis Treatment by Type

    Primary Hyperhidrosis

    Secondary Generalized Hyperhidrosis

    Latin America Hyperhidrosis Treatment by End-User

    Dermatology Clinics

    Ambulatory Surgery Centers

    Payers/Patients

    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials